Opiate addiction therapy is evidence-based medical care that pairs medications, behavioral treatments, and harm-reduction strategies to reduce overdose risk and restore day-to-day functioning. This article explains the evidence for methadone, buprenorphine, and naltrexone, when supervised withdrawal is appropriate, which psychosocial therapies improve outcomes, and practical next steps for finding coordinated care at Resolutions Medical Services.
How opiate dependence changes the brain and why treatment is medical care
Key point: Opiate dependence produces measurable changes in brain chemistry and circuits that drive tolerance, persistent craving, and impaired decision making rather than merely a willpower problem.
At the receptor level, repeated opioid exposure reduces mu opioid receptor responsiveness and downregulates endogenous opioid signaling. At the circuit level, reward pathways including the ventral tegmental area and nucleus accumbens shift baseline activity, while the prefrontal cortex that supports impulse control and planning becomes less effective. Those biological shifts explain why withdrawal symptoms can be intense, why small stressors trigger relapse, and why sudden discontinuation leads to high overdose risk when tolerance has fallen.
Clinical consequences and why this is medical care
Clinical consequence: Because the brain adapts, symptom control requires either pharmacologic receptor stabilization or a carefully managed transition to abstinence under medical supervision. Medications such as methadone and buprenorphine restore receptor occupancy and blunt cravings; antagonist strategies such as naltrexone block receptor effects but require full detox first.
- Why detox alone often fails: Medically supervised withdrawal removes drug effects but leaves the altered reward and stress circuits intact, producing very high relapse risk if follow-up treatment is not provided.
- Why retention matters: Long term engagement with medication-assisted treatment correlates with lower overdose mortality and better social functioning in the real world.
- Co-occurring conditions change the equation: Untreated depression, PTSD, pain, or infectious disease raise relapse risk and must be part of the medical plan.
Practical tradeoff: Choosing an initial treatment involves tradeoffs between accessibility and potency. Methadone is a full agonist with strong retention but requires opioid treatment program enrollment and often daily visits. Buprenorphine is office based and safer in unsupervised settings but in some patients yields lower retention than methadone. Those differences matter for real patients balancing work, childcare, and transport.
Concrete example: A 34 year old patient arrives after an emergency department naloxone reversal and wants to avoid another overdose. Starting buprenorphine the same day stabilized withdrawal and cravings, allowing the patient to enroll in outpatient therapy, reengage at work, and accept a naloxone kit for home. Without medication that patient likely would have cycled through short detox episodes and returned to unsafe use.
Common misjudgment: Many clinicians and families expect short detox to be curative. In practice, brief medically managed withdrawal without rapid linkage to ongoing medication and psychosocial support is one of the main failure modes seen in the clinic.
Treatment is medical care because it targets altered brain systems that govern craving, stress response, and risk taking; addressing those systems reduces overdose and supports recovery.
Actionable next step: If a patient is leaving detox, ensure immediate linkage to medication-assisted treatment or documented follow up with an addiction clinician.
Medication-assisted treatment overview and principles
Direct point: Medication-assisted treatment is not an optional add-on; it is the structural platform for effective opiate addiction therapy because it stabilizes physiology while psychosocial work proceeds.** Patients who can access and remain on appropriate medication are the ones who show real reductions in unregulated opioid use and avoid fatal overdoses in clinical practice.
Core goals and how medications fit
What MAT aims to do: Reduce illicit opioid use, prevent overdose, improve retention in care, and restore day-to-day functioning so behavioral interventions can take effect.** Medication is the durable part of that equation; counseling, case management, and social supports are the mobilizable parts that convert stability into recovery gains.
Selection matters more than ideology. Choose between methadone, buprenorphine (Suboxone/Subutex), and naltrexone based on dependency severity, pregnancy status, prior treatment response, co-occurring psychiatric or medical conditions, access constraints, and the patient’s goals. Regulatory and local availability often determine what is practical—office-based buprenorphine is easier for many patients, while methadone programs offer stronger retention for high tolerance or unstable social situations.
- Practical tradeoff: Methadone gives higher retention but requires opioid treatment program enrollment and often daily attendance.
- Access tradeoff: Buprenorphine is safer for unsupervised use and can be prescribed in outpatient settings; recent regulatory changes have expanded prescribing but state rules still vary.
- Clinical limitation: Naltrexone requires full detox and carries higher early discontinuation risk; reserve for highly motivated patients or where agonist therapy is contraindicated.
Operational insight: Induction timing is a practical pain point. Starting buprenorphine too early causes precipitated withdrawal; delaying leaves patients exposed to relapse. In experienced programs, strategies like low-dose or microinduction reduce that risk, but these require clinician skill and clear protocols rather than informal experimentation.
Concrete example: A 29 year old pregnant person with daily heroin use was enrolled directly into a local methadone program. Stabilization on methadone allowed coordinated prenatal care, hepatitis C screening, and social work support, avoiding multiple short detox attempts that previously interrupted prenatal visits and increased risk to both patient and fetus.
Judgment call clinicians should make: Low-barrier, flexible delivery beats rigid rules. Excessive urine testing, punitive take-home policies, or delayed linkage after detox commonly push people away. If system constraints force a choice, offer an accessible agonist option (buprenorphine or methadone) and immediate naloxone rather than defaulting to stand-alone detox.
Key point: Match medication choice to the person’s life logistics and medical needs; the best medication is the one the patient can actually get and stay on.
Actionable takeaway: When arranging opiate addiction therapy, prioritize rapid access to an evidence-based medication and a plan for follow-up psychosocial care.
Methadone maintenance therapy
Direct observation matters. Methadone treatment is delivered through certified opioid treatment programs (OTPs) with on site dosing and structured clinical oversight rather than as a take home prescription from a primary care office. That delivery model is deliberate: it supports safety monitoring, supervised initiation, and a predictable pathway to gradually expanded take home doses when patients demonstrate stability.
What it does in practice
Clinical effect: Methadone provides sustained opioid receptor activation that reduces craving and normalizes function for patients with high tolerance or chaotic use patterns. In real world practice this translates to better retention in care for people who otherwise cycle through short detox episodes and repeat overdoses.
Important limitation: Because methadone is a full opioid agonist, it carries greater respiratory depression risk when combined with sedatives or heavy alcohol use. Programs must balance dose adequacy against safety concerns, monitor for cardiac conduction issues in select patients, and have clear protocols for polysubstance use.
Operational tradeoff: The OTP structure increases access barriers for some patients – daily travel, work conflicts, childcare challenges, and stigma at clinic windows are real obstacles. However, for patients with unstable housing, high-frequency use, or prior failed outpatient buprenorphine, the tighter supervision often produces measurable reductions in illicit opioid use and mortality.
- Check before you enroll: Ask about take home policies and the timeline for earning take home doses so you can plan around work or family demands
- Safety measures to expect: Routine clinical assessments, occasional ECGs when indicated, and coordinated counseling or case management integrated into the program
- Division of responsibilities: OTPs handle dosing and medical oversight; outpatient therapists or community programs typically provide behavioral therapy and vocational supports
Concrete example: A 42 year old patient with long standing, high tolerance opioid use lost housing and could not reliably make weekly clinic appointments. Enrollment in an OTP provided daily supervised dosing and rapid referral to housing services. After three months of consistent attendance and negative urine screens for illicit opioids, the patient qualified for expanded take home privileges and began part time work, which would not have been feasible during repeated short detox attempts.
Practitioner judgment: Methadone is not simply a stronger medication option. It is a service model that pairs pharmacology with frequent clinical contact. For patients whose life circumstances make daily structure necessary, methadone programs usually outperform office based alternatives. For patients who cannot meet daily clinic requirements, prioritize rapid linkage to buprenorphine or flexible care pathways rather than forcing an impractical OTP plan.
If considering methadone, evaluate access logistics, co-occurring sedative use, and the programs plan for take home dosing and behavioral supports before starting care.
Practical next step: If methadone is a fit, call the local OTP to confirm intake hours, what documentation is needed, and whether the program coordinates wraparound services.
Buprenorphine treatments including Suboxone and Subutex
Bottom line: Buprenorphine is the most practical office based medication for many people with opioid use disorder because it stabilizes cravings and withdrawal while allowing patients to keep work, family, and outpatient counseling commitments as part of their opiate addiction therapy.
Formulations, pharmacology, and why the difference matters
Basic distinction: Suboxone combines buprenorphine with naloxone to discourage injection; Subutex is buprenorphine alone. Both reduce opioid cravings and overdose risk compared with no medication, but the naloxone component changes how clinicians think about diversion and pregnancy management in real practice.
Key clinical tradeoff: Buprenorphine has a ceiling effect for respiratory depression, making it safer than full agonists in unsupervised settings, but induction timing creates real operational risk – start too early and the patient can experience precipitated withdrawal; start too late and the patient may relapse before induction. Microinduction techniques reduce that tradeoff but require trained teams and written protocols.
- Induction considerations: Assess recent opioid use, time since last dose, and prepare for observed initiation or a documented microinduction pathway.
- Co-use risks: Buprenorphine is safer than methadone for overdose in isolation but combined sedative use – benzodiazepines or heavy alcohol – still increases respiratory depression risk and requires tight coordination with behavioral health and primary care.
- Access and retention: Office based buprenorphine improves access and keeps patients engaged in outpatient rehab programs, but for some with very high tolerance or chaotic social circumstances, methadone maintenance therapy may deliver better retention.
Concrete example: A 26 year old with daily prescription opioid misuse kept a full time job and could not attend daily clinic dosing. The clinician offered same day Suboxone induction with brief counseling and scheduled CBT sessions. When the patient experienced mild precipitated withdrawal after an early dose, the team switched to a microinduction protocol and continued outpatient buprenorphine while the patient completed a short course of contingency management counseling, avoiding inpatient detox and preserving work attendance.
Judgment call clinicians should make: Prioritize low barrier, flexible buprenorphine delivery rather than rigid rules that require multiple clinic visits before a first dose. In practice, programs that offer same day starts, telemedicine follow ups, and coordinated behavioral therapy for addiction retain more patients and reduce overdose events. Co-prescribe naloxone for opioid overdose and integrate routine screening for sedative use.
Suboxone versus Subutex is often less important than speed of access and quality of follow up; get medication into the person who is willing to engage and pair it with behavioral therapy for addiction.
Actionable next step: If you are arranging buprenorphine treatment, ask whether a provider can offer same day induction, microinduction options, and co-located counseling. For local outpatient buprenorphine treatment and intake at Resolutions Medical Services.
Naltrexone and extended-release Vivitrol
Straight answer: Naltrexone is an opioid antagonist; the monthly injectable formulation Vivitrol provides a pharmacologic blockade of opioid effects for roughly 28–30 days and removes agonist activity from the treatment equation.
Mechanism, induction barriers, and practical consequences
How it differs from agonists: Unlike methadone or buprenorphine, naltrexone does not occupy opioid receptors in a tolerizing, stabilizing way — it blocks them. That means it will precipitate acute withdrawal if opioids are still present, so patients must be reliably opioid-free before starting. In practice that induction requirement is the single largest operational barrier to success.
- Strength: Vivitrol is useful where opioid agonists are unacceptable or restricted, for patients who prefer a non-opioid approach, or in supervised settings such as some criminal justice programs.
- Limitation: The need for a confirmed opioid-free interval raises dropout risk; many patients leave treatment between detox and their first injection.
- Safety tradeoff: Blocking receptors reduces acute intoxication risk while maintained, but loss of tolerance after blockade means overdose risk climbs rapidly if the person returns to opioid use after stopping naltrexone.
- Operational: Vivitrol is costly and often requires prior authorization; clinics must coordinate medically supervised withdrawal, insurance paperwork, and an injection schedule.
Clinical judgment: Randomized trials show extended-release naltrexone can reduce opioid use in carefully selected, detoxified patients, but head-to-head comparisons often find higher early discontinuation than with agonist treatments. That is not a failure of the drug; it is a predictable consequence of the induction hurdle and adherence demands. For many patients, an agonist strategy delivers better retention and mortality benefit.
Use case: A 36 year old on probation who cannot be prescribed methadone and does not want daily medication completed a seven day inpatient withdrawal, received counseling, and accepted monthly Vivitrol injections. The single monthly appointment simplified adherence under legal supervision and reduced opportunities for unsanctioned opioid use while community supports were established.
If you consider Vivitrol, plan the entire induction pathway before detox ends: documented opioid-negative testing, on-site injection availability, naloxone provision, and a contingency plan for missed doses.
Actionable steps: Coordinate medically supervised detox, confirm opioid abstinence window, obtain prior authorization early, schedule the first Vivitrol injection at the time of discharge, and prescribe naloxone with overdose education.
Managing acute withdrawal and evidence-based symptom control
Immediate reality: Medically supervised withdrawal is a short window for safety and symptom control, not a cure. The clinical objective during this phase is to stabilize autonomic symptoms, prevent complications, and create a safe pathway onto ongoing therapy — ideally an evidence-based medication strategy such as Medication-Assisted Treatment.
Treatment options for withdrawal symptoms fall into two categories: medications that reduce opioid receptor-driven craving and allow induction onto agonist/antagonist therapy and symptom-targeted agents that address nausea, diarrhea, insomnia, and sympathetic overactivity. Use both if needed; relying solely on symptomatic pills without planning next-step MAT is a common failure mode.
Medications and practical tradeoffs
Alpha-2 agonists: Lofexidine (Lucemyra) and clonidine reduce sympathetic overdrive. Practical tradeoff: clonidine is inexpensive but often causes hypotension and drowsiness; lofexidine was developed specifically for opioid withdrawal and tends to have fewer blood pressure effects but is costlier and may be subject to prior authorization. Choose based on the patient medical profile, monitoring capacity, and payer realities.
Symptom-directed care: Treat nausea, diarrhea, and sleep disruption with routine antiemetics, loperamide, trazodone or hydroxyzine as clinically appropriate. These relieve suffering and improve retention, but they do not lower relapse or mortality unless paired with a transition plan to ongoing therapy.
- When to prefer inpatient medically managed withdrawal: severe cardiopulmonary disease, pregnancy complications requiring obstetric monitoring, uncontrolled polysubstance use (benzodiazepines or heavy alcohol), or suicidal ideation.
- When outpatient symptom control is reasonable: stable vitals, reliable caregiver or housing, and rapid linkage to outpatient buprenorphine or a local opioid treatment program.
- Operational point: whichever setting you choose, schedule the first follow-up visit or MAT induction before discharge — same-day or next-business-day handoffs dramatically improve outcomes.
Real-world use case: A 31 year old with high fentanyl exposure presented with severe withdrawal and homelessness. Clinicians started lofexidine for autonomic symptoms while initiating a buprenorphine microinduction over 48 hours; because the clinic arranged same-week counseling and a follow-up prescription, the patient remained engaged and avoided a repeat detox cycle.
A judgment most clinicians should make up front: rigidity kills retention. Insisting on a prolonged, opioid-free period before offering any medication often pushes people back into unsafe use. When feasible, combine short-term symptom control with protocols for rapid buprenorphine induction (including microinduction techniques when necessary) or direct referral to methadone programs; that pairing is what converts a stabilization episode into durable engagement.
Symptom control medications are a bridge, not the destination: use them to keep people safe and connected until an evidence-based long-term plan is in place.
Clinical checklist before discharge: confirm naloxone provision and overdose education, document plan for MAT or OTP referral, reconcile co-prescribed sedatives, choose lofexidine versus clonidine based on cardiac and orthostatic risk, and schedule follow-up within 24–72 hours.
Behavioral therapies and psychosocial supports that improve outcomes
Direct point: Behavioral therapies and structured psychosocial supports convert the physiologic stabilization achieved by medication into reduced illicit use, safer choices, and improved function. Medication without a plan for behavior change and social support is unstable in practice.
Core modalities and how they add value
Cognitive behavioral therapy: Focuses on identifying high risk situations, restructuring thinking that leads to use, and building coping skills. CBT works best when scheduled regularly over weeks to months and when therapists link homework to real life goals like work or parenting.
Contingency management: Uses short term tangible incentives to reinforce abstinence or attendance. This method produces some of the largest effect sizes for reducing use in randomized trials, but programs must budget incentives and plan for what happens when rewards end.
Motivational interviewing and trauma informed care: These approaches reduce defensive disengagement and are essential when ambivalence, trauma, or co-occurring mental health conditions are present. In practice, brief MI sessions before induction increase engagement in follow up therapy.
Family therapy and peer supports: Family interventions repair relationships and improve adherence when family members can participate constructively. Peer recovery coaching and community based groups provide practical navigation, role modeling, and local accountability that many formal therapies cannot replicate.
Practical tradeoff: Intensity versus accessibility matters. Intensive outpatient programs with multiple weekly sessions produce better functional gains for people with unstable housing or co-occurring disorders, but they require time and transport that some individuals cannot provide. Lighter, flexible models plus strong case management often achieve better real world retention than a rigid high intensity program people cannot attend.
- When to prioritize CBT: patients with cognitive readiness and a stable schedule who need skills to manage triggers
- When to use contingency management: short term goals like early abstinence, clinic attendance, or medication adherence where quick reinforcement helps
- When family therapy matters most: active family system with potential for positive involvement or when child custody is a treatment factor
Concrete example: A community clinic combined same day buprenorphine induction, weekly CBT, and a 12 week contingency management program that rewarded negative urine tests with grocery vouchers. Attendance rose from 40 percent to 75 percent over three months, the majority of patients kept employment, and several moved into sober living homes with peer coaching support.
Practitioner judgment: Behavioral interventions are not interchangeable. In routine practice, CBT plus contingency management produces faster reductions in use, but sustaining gains requires social supports, housing stability, and attention to mental health. Programs that treat behavioral therapy as optional tend to see higher dropout rates than programs that actively schedule and reimburse these services.
Behavioral therapy is the mechanism that turns pharmacologic stability into real life change; prioritize modalities to match a persons readiness, logistics, and co-occurring needs.
Harm reduction, overdose prevention, and medical comorbidity care
Core point: Naloxone access, practical harm reduction measures, and proactive management of infections and other medical comorbidities are essential components of effective opiate addiction therapy, not optional extras. Integrating these steps into every intake or discharge prevents deaths and reduces downstream complications that derail recovery efforts.
Overdose prevention that actually reaches people
Make naloxone routine. Clinicians should offer naloxone to anyone at risk of an opioid overdose, their household members, and relevant community partners, and provide brief, hands-on training for use. Where available, use standing-order programs so patients leave with a kit that contains Narcan and clear instructions rather than a paper prescription they may never fill. See CDC guidance on community overdose prevention for program models and distribution strategies: CDC Opioid Overdose.
Practical tradeoff: Pharmacy availability, out-of-pocket cost, and stigma at the counter are real access barriers. When pharmacies are slow or patients refuse to pick up, clinics should keep devices on site and train staff to hand them out at first contact. Co-prescribing naloxone alongside medication-assisted treatment reduces fatal outcomes even when patients are not yet ready to stop use.
Safer-use tools are useful but limited. Fentanyl test strips and safer-use counseling reduce some acute risks but are not a guarantee against overdose. Teach people how to use strips, interpret results, and combine test results with other precautions: never use alone, use small test doses, and keep naloxone within reach. Be candid about limitations: test strips do not measure potency or detect every analog.
Medical comorbidity care saves lives and preserves recovery windows. Actively screen for hepatitis C, HIV, bacterial infections, and mental health conditions at first contact and treat or link immediately. Direct-acting antivirals cure hepatitis C in most people and should not be deferred because of ongoing substance use; offering integrated HCV treatment in addiction settings improves uptake. Offer HIV testing and discuss PrEP when indicated, and ensure vaccinations for hepatitis A, hepatitis B, and tetanus are up to date.
Clinicians who silo infectious disease care from addiction care lose opportunities. Co-located or closely coordinated services increase retention and reduce preventable morbidity.
Concrete example: After an ED naloxone reversal, a clinic team provided an on-site naloxone kit and quick training, performed rapid HCV antibody testing, and started same-day buprenorphine induction with a scheduled follow-up at Resolutions Medical Services. That single coordinated handoff prevented a gap in care, addressed infectious disease risk, and created a clear path to ongoing opiate addiction therapy.
Practical checklist for front-line clinicians: give naloxone and brief training at discharge; offer same-day MAT linkage or a clear appointment within 72 hours; perform point-of-care HCV/HIV testing and arrange treatment linkage; provide safer-use counseling and fentanyl test strips where legal; and document a follow-up plan with contact info (see Resolutions Services for local coordination).
Creating personalized treatment plans and long-term recovery strategies
Start with immediate risk and goal alignment: Before selecting medications or programs, assess overdose risk, current housing and childcare constraints, co-occurring mental health or pain conditions, and what the person wants to achieve. Safety measures — naloxone in hand, clear follow-up within 24–72 hours, and a documented plan for medication access — are nonnegotiable foundations of any opiate addiction therapy plan.
Core components of a personalized plan
- Stabilize then select medication: Choose the medication strategy that matches clinical need and life logistics — immediate buprenorphine for those who must keep work or family commitments, methadone for people needing daily supervised structure, or naltrexone when a non-agonist approach is required. Balance efficacy with access and safety.
- Pair pharmacology with psychosocial supports: Assign a primary behavioral modality (CBT, contingency management, family therapy) tied to measurable objectives like attendance, reduced use, or improved functioning; attach case management for housing, employment, and legal needs.
- Define measurable, time‑bound goals: Use concrete markers (weeks engaged, negative tests if agreed, employment or parenting milestones) and schedule periodic review to adjust dose, modality intensity, or setting.
- Plan for lapses and transitions: Build a rapid re-engagement protocol, harm reduction steps (naloxone, safer-use counseling), and a pathway back onto medication quickly rather than punitive discharge.
- Coordinate continuity: Document who prescribes, who provides counseling, how lab work and infectious disease care are handled, and whether telemedicine or home pick-up of naloxone is available.
Tradeoff to acknowledge: Longer duration on agonist therapy reduces mortality and supports stability, but patient and system pressures push for early tapering. In practice, insistence on short courses because of ideology or cost leads to repeated detox cycles and higher overdose risk. Treat duration as clinical, not moral — decisions should follow stability and risk, not arbitrary timelines.
Concrete example: A 38 year old single parent using prescription opioids for chronic back pain wanted custody stability and could not do daily clinic visits. The team started office-based buprenorphine with a family therapy schedule, arranged telemedicine check-ins around school drop-off times, issued naloxone, and linked the parent to vocational counseling. Within two months the patient reduced illicit use, maintained employment, and documented improved parenting stability, while the plan retained flexibility for dose adjustments.
Judgment clinicians should apply: Low-barrier access plus deliberate coordination beats rigid protocol. That means same-week induction or a documented microinduction pathway when appropriate, scheduled behavioral appointments that fit life logistics, and preapproved contingency actions for missed visits. Systems that force people through bureaucratic hoops lose them — and that failure costs lives.
Coordination checklist before discharge or first visit: Confirm naloxone provision; assign a prescriber and behavioral contact with next appointment booked; document contingency return steps for missed doses; screen and link for HCV/HIV care; and confirm who will manage prescriptions or OTP referrals.
How Resolutions Medical Services implements evidence-based opiate addiction therapy
Direct approach: Resolutions designs care around rapid, pragmatic access to proven treatments — low-barrier medication-assisted treatment, integrated behavioral therapy, and built-in overdose prevention rather than a sequence of referrals that lose people between steps.
Clinical team and accountability: Our model is physician-led (addiction medicine credentialed), supported by licensed therapists, nurse care coordinators, and peer recovery coaches. That mix matters in practice — protocols for induction, monitoring, and contingency management reduce errors that happen when medication and therapy are managed separately.
Operational tactics and tradeoffs: We offer same-day buprenorphine starts and documented microinduction pathways to avoid precipitated withdrawal, coordinate referrals to opioid treatment programs for methadone maintenance, and pre-plan Vivitrol induction with prior authorization to minimize gaps. Limitation to accept: insurance authorizations and OTP capacity still create delays; when demand exceeds slots we prioritize high-risk patients and use telemedicine and naloxone distribution to keep others safer while they wait.
How intake to ongoing care happens (typical workflow)
- Rapid intake (within 24 hours): focused medical risk check, overdose history, and medication history.
- Immediate stabilization: same-day buprenorphine induction or expedited OTP placement; if detox is needed, symptom control with lofexidine or clonidine plus a clear handoff.
- Concurrent psychosocial plan: schedule CBT, contingency management, or family therapy within the first week and assign a peer coach.
- Harm reduction and medical screening: provide naloxone on-site, rapid HCV/HIV testing, and linkage for treatment as needed.
- Continuity and data follow-up: case management confirms appointments, documents missed visits, and triggers rapid re‑engagement steps rather than punitive discharge.
Practical example: A person arrives after an ED naloxone reversal and is referred to Resolutions. They receive a same-day intake, begin a buprenorphine induction under observation, leave with a naloxone kit and a scheduled CBT slot for the next week, and are given a peer coach phone number for day-to-day support. That single coordinated sequence — not a stack of separate appointments — prevents the common gap where patients leave detox without ongoing medication or supports.
Judgment we apply: Low-barrier access plus pragmatic harm reduction saves lives more reliably than ideological purity about abstinence. In our experience, programs that insist on long preconditions for medication lose the very people at highest risk of overdose. Where constraints exist (OTP waitlists, authorizations), honest triage and harm reduction are the morally and clinically correct fallback.
Same-day medication starts, on-site naloxone, and a booked behavioral appointment within one week are the elements that convert short-term stabilization into sustained engagement.
How to connect: Call or request an intake at Resolutions Medical Services Contact for rapid assessment; bring a photo ID, list of current medications, and any insurance information.